MDNews - Cleveland-Akron-Canton

November/December 2018

Issue link: https://viewer.e-digitaledition.com/i/1062971

Contents of this Issue

Navigation

Page 11 of 23

A Burgeoning Issue The number of U.S. children with food allergies increased by 50 percent between 1997 and 2011, according to the CDC. STUDY: Omalizumab Boosts Safety, Efficacy of Oral Immunotherapy for Multifood Allergies BY JOSH GARCIA THE IMMUNOGlOBUlIN E-BlOCKING DRUG OMAlIZUMAB lIMITED THE RISK OF ADVERSE EFFECTS A SSOCIATED WITH OR Al IMMUNOTHER APY (OIT) AND INCRE A SED OIT'S OVER All EFFICACY IN PARTICIPANTS WITH MUlTIPlE FOOD AllERGIES, A PHA SE 2 ClINICAl TRIAl AT STANFORD UNIVERSIT Y FOUND. F O O D A L L E R G I E S AFFECT 4 to 6 percent o f c h i l d r e n i n t h e United States; 30 per- cent of those children have allergies to multiple foods. Despite the serious nature of some allergic reactions and the rising prevalence of food allergies, no approved treatment exists beyond avoiding triggers a n d c a r r y i n g epi neph r i ne i n c a s e of emergency. OIT'S LIMITATIONS The risk of adverse events has kept OIT from being approved to treat food allergies as well, but lack of treatment options has spurred a number of studies on this approa ch , wh ich i nvolves ex posi n g patients to food allergens in small but steadily increasing amounts to raise their tolerance to triggers. W hile some patients in clinica l tria ls become desensitized to sma ll a mounts of foods, few achieve full desensitiza- t i on , s a y s M a rk G l a u m , M D, Ph D, A ssociate Professor of Medicine a nd Pediatrics, A llerg y a nd Immunolog y at t h e Un i v e r s i t y o f S o u t h F l o r i d a 's Morsa ni College of Medicine. Moreover, comparatively few studies have exa mined OIT 's eff ectiveness in a dd r e s si n g mu lt iple fo o d a l ler g ie s simulta neously, a nd due to the leng th of time OIT requires — months in some ca ses — bu i ld i n g desen sit i zat ion t o mu ltiple a l lerg ies cou ld ta ke yea rs if they were addressed one at a time. That mea n s i ncrea sed cos t a nd i nconve - nience for patients should OIT become a n accepted treatment method. ENTER OMALIZUMAB T he sea rch for i mproved sa fet y a nd eff icacy during OIT has led to research, published in Allergy, Asthma & Clinical Immunology and elsewhere, on combin- i n g OI T w it h t he a d m i n i s t rat ion of oma lizumab. 1 2

Articles in this issue

Archives of this issue

view archives of MDNews - Cleveland-Akron-Canton - November/December 2018